Quarterly Financial Data (Unaudited and restated)

12 Months Ended

Dec. 31, 2022

Quarterly Financial Data (Unaudited and restated)

Quarterly Financial Data (Unaudited and restated)

17.        Quarterly Financial Data (Unaudited and restated)

The Company is providing restated quarterly unaudited consolidated financial information for interim periods June 30, 2022 and September 30, 2022.

The restated consolidated balance sheet line items for the second through third fiscal quarters of 2022 are as follows:

	June 30, 2022
	As Previously Reported		Adjustments		As Restated
Deferred tax liability	$	3,541,937	$	(3,326,000)	$	215,937
Total Liabilities		36,467,130		(3,326,000)		33,141,130
Accumulated deficit		(183,996,826)		3,326,000		(180,670,826)
Total Stockholders' Equity - NightHawk Biosciences, Inc.		96,638,241		3,326,000		99,964,241
Total Stockholders' Equity	$	95,387,663	$	3,326,000	$	98,713,663
	September 30, 2022
	As Previously Reported		Adjustments		As Restated
Goodwill	$	3,467,747	$	(253,000)	$	3,214,747
Total Assets		120,164,913		(253,000)		119,911,913
Deferred tax liability		3,326,000		(3,326,000)		—
Total Liabilities		37,039,188		(3,326,000)		33,713,188
Accumulated deficit		(197,002,176)		3,073,000		(193,929,176)
Total Stockholders' Equity - NightHawk Biosciences, Inc.		84,465,725		3,073,000		87,538,725
Total Stockholders' Equity	$	83,125,726	$	3,073,000	$	86,198,726

The restated line items of the consolidated statements of operations and comprehensive loss for the second through third fiscal quarters of 2022 are as follows:

	Three Months Ended		Six Months Ended		Three Months Ended		Six Months Ended		Three Months Ended		Six Months Ended
	June 30, 2022				June 30, 2022				June 30, 2022
	As Previously reported				Adjustments				As Restated
Income tax benefit	$	—	$	—	$	3,326,000	$	3,326,000	$	3,326,000	$	3,326,000
Net loss		(10,263,910)		(18,453,708)		3,326,000		3,326,000		(6,937,910)		(15,127,708)
Net loss attributable to NightHawk Biosciences, Inc.		(10,157,286)		(18,277,873)		3,326,000		3,326,000		(6,831,286)		(14,951,873)
Net loss per share, basic and diluted	$	(0.40)	$	(0.71)	$	0.13	$	0.13	$	(0.27)	$	(0.58)
Total comprehensive loss		(10,114,055)		(18,359,122)		3,326,000		3,326,000		(6,788,055)		(15,033,122)
Comprehensive loss - NightHawk Biosciences, Inc.	$	(10,007,431)	$	(18,183,287)	$	3,326,000	$	3,326,000	$	(6,681,431)	$	(14,857,287)

	Three Months Ended		Nine Months Ended		Three Months Ended		Nine Months Ended		Three Months Ended		Nine Months Ended
	September 30, 2022				September 30, 2022				September 30, 2022
	As Previously reported				Adjustments				As Restated
Income tax benefit	$	215,937	$	215,937	$	(253,000)	$	3,073,000	$	(37,063)	$	3,288,937
Net loss		(13,094,771)		(31,548,479)		(253,000)		3,073,000		(13,347,771)		(28,475,479)
Net loss attributable to NightHawk Biosciences, Inc.		(13,005,350)		(31,283,223)		(253,000)		3,073,000		(13,258,350)		(28,210,223)
Net loss per share, basic and diluted	$	(0.51)	$	(1.22)	$	(0.01)	$	0.12	$	(0.52)	$	(1.10)
Total comprehensive loss		(12,979,112)		(31,338,234)		(253,000)		3,073,000		(13,232,112)		(28,265,234)
Comprehensive loss - NightHawk Biosciences, Inc.	$	(12,889,691)	$	(31,072,978)	$	(253,000)	$	3,073,000	$	(13,142,691)	$	(27,999,978)

While the adjustments changed the deferred tax liability line item in the unaudited consolidated statements of cash flows, they did not have an impact on total net cash provided by operating activities, net cash used in investing activities, or net cash (used in) provided by financing activities for any of the applicable periods.

The restated line items of the unaudited consolidated statements of cash flows for the second through third fiscal quarters of 2022 are as follows:

	For the Six Months Ended,		For the Nine Months Ended,		For the Six Months Ended,		For the Nine Months Ended,		For the Six Months Ended,		For the Nine Months Ended,
	June 30, 2022		September 30, 2022		June 30, 2022		September 30, 2022		June 30, 2022		September 30, 2022
	As Previously Reported				Adjustments				As Restated
Net loss	$	(18,453,708)	$	(31,548,479)	$	3,326,000	$	3,073,000	$	(15,127,708)	$	(28,475,479)
Adjustments to reconcile net loss to net cash used in operating activities:
Deferred tax liability	$	—	$	(215,937)	$	(3,326,000)	$	(3,073,000)	$	(3,326,000)	$	(3,288,937)